LD2-3

Overview

LD2-3 is a cytotoxic compound derived from Exatecan ( HY-13631 ), designed to be conjugated with anti- FGFR2b or anti- CEA antibodies to form intact antibody-drug conjugate (ADC) molecules. LD2-3 exhibits a remarkable bystander killing effect: it not only effectively kills FGFR2b-positive tumor cells, but also eliminates surrounding FGFR2b-negative cells in co-culture and mixed tumor xenograft models, thereby inducing complete tumor regression. LD2-3 can be used for anti-tumor research in relevant fields such as gastric cancer and lung cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > ADC Payloads | Products > Signaling Pathways > Topoisomerase

Product Information

• Catalog No.: HY-178238
• CAS No.: 3040077-52-6
• Molecular Formula: C59H74FN11O18
• Molecular Weight: 1244.28
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source